34 related articles for article (PubMed ID: 16271075)
1. CD30 Expression and Its Functions during the Disease Progression of Adult T-Cell Leukemia/Lymphoma.
Nakashima M; Uchimaru K
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240076
[TBL] [Abstract][Full Text] [Related]
2. Triple combination of BET plus PI3K and NF-κB inhibitors exhibit synergistic activity in adult T-cell leukemia/lymphoma.
Daenthanasanmak A; Bamford RN; Yoshioka M; Yang SM; Homan P; Karim B; Bryant BR; Petrus MN; Thomas CJ; Green PL; Miljkovic MD; Conlon KC; Waldmann TA
Blood Adv; 2022 Apr; 6(7):2346-2360. PubMed ID: 35030628
[TBL] [Abstract][Full Text] [Related]
3. Novel targeted therapies of T cell lymphomas.
Iżykowska K; Rassek K; Korsak D; Przybylski GK
J Hematol Oncol; 2020 Dec; 13(1):176. PubMed ID: 33384022
[TBL] [Abstract][Full Text] [Related]
4. Importin β1 regulates cell growth and survival during adult T cell leukemia/lymphoma therapy.
Ishikawa C; Senba M; Mori N
Invest New Drugs; 2021 Apr; 39(2):317-329. PubMed ID: 32959166
[TBL] [Abstract][Full Text] [Related]
5. Proteomic profiling of HTLV-1 carriers and ATL patients reveals sTNFR2 as a novel diagnostic biomarker for acute ATL.
Guerrero CLH; Yamashita Y; Miyara M; Imaizumi N; Kato M; Sakihama S; Hayashi M; Miyagi T; Karimata K; Uchihara J; Ohshiro K; Todoroki J; Nakachi S; Morishima S; Karube K; Tanaka Y; Masuzaki H; Fukushima T
Blood Adv; 2020 Mar; 4(6):1062-1071. PubMed ID: 32196559
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment.
Ratner L
Front Microbiol; 2019; 10():2109. PubMed ID: 31620102
[TBL] [Abstract][Full Text] [Related]
7. Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.
Ishikawa C; Senba M; Mori N
Oncol Lett; 2018 Apr; 15(4):5311-5317. PubMed ID: 29552172
[TBL] [Abstract][Full Text] [Related]
8. Human T-cell lymphotropic virus type 1 and its oncogenesis.
Zhang LL; Wei JY; Wang L; Huang SL; Chen JL
Acta Pharmacol Sin; 2017 Aug; 38(8):1093-1103. PubMed ID: 28392570
[TBL] [Abstract][Full Text] [Related]
9. Efficiency of AUY922 in mice with adult T-cell leukemia/lymphoma.
Ishikawa C; Senba M; Mori N
Oncol Lett; 2016 Jul; 12(1):387-392. PubMed ID: 27347156
[TBL] [Abstract][Full Text] [Related]
10. The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy.
Berghella AM; Pellegrini P; Del Beato T; Ciccone F; Contasta I
Cancer Immunol Immunother; 2011 Oct; 60(10):1373-81. PubMed ID: 21739118
[TBL] [Abstract][Full Text] [Related]
11. Development and validation of a fluorescent microsphere immunoassay for soluble CD30 testing.
Pavlov I; Martins TB; Delgado JC
Clin Vaccine Immunol; 2009 Sep; 16(9):1327-31. PubMed ID: 19605595
[TBL] [Abstract][Full Text] [Related]
12. Increased serum levels of soluble CD30 in patients with common variable immunodeficiency and its clinical implications.
Rezaei N; Haji-Molla-Hoseini M; Aghamohammadi A; Pourfathollah AA; Moghtadaie M; Pourpak Z
J Clin Immunol; 2008 Jan; 28(1):78-84. PubMed ID: 17912490
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of serum neuron-specific enolase in patients with adult T-cell leukemia.
Fujiwara H; Arima N; Ohtsubo H; Matsumoto T; Kukita T; Kawada H; Imaizumi R; Ozaki A; Matsushita K; Tei C
Am J Hematol; 2002 Oct; 71(2):80-4. PubMed ID: 12353304
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of CD30 in adult T-cell leukemia cell lines: possible role in constitutive NF-kappaB activation.
Higuchi M; Matsuda T; Mori N; Yamada Y; Horie R; Watanabe T; Takahashi M; Oie M; Fujii M
Retrovirology; 2005 May; 2():29. PubMed ID: 15876358
[TBL] [Abstract][Full Text] [Related]
15. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
[TBL] [Abstract][Full Text] [Related]
16. Progress in adult T cell leukemia research.
Hanaoka M
Acta Pathol Jpn; 1982; 32 Suppl 1():171-85. PubMed ID: 6764996
[TBL] [Abstract][Full Text] [Related]
17. Blocking NF-kappaB as a potential strategy to treat adult T-cell leukemia/lymphoma.
Horie R; Watanabe T; Umezawa K
Drug News Perspect; 2006 May; 19(4):201-9. PubMed ID: 16823495
[TBL] [Abstract][Full Text] [Related]
18. Serum level of soluble CD30 correlates with the aggressiveness of adult T-cell leukemia/lymphoma.
Nishioka C; Takemoto S; Kataoka S; Yamanaka S; Moriki T; Shoda M; Watanabe T; Taguchi H
Cancer Sci; 2005 Nov; 96(11):810-5. PubMed ID: 16271075
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
